NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading AKBA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story. AKBA is currently loss-making but has shown strong recent financial performance, particularly in expanding its Vafseo revenue. The current thesis state is intact, with management focused on growth despite elevated risks.
The market seems to have priced in a low level of fragility, with a valuation that is considered cheap compared to peers. However, there is an expectations gap, indicating that the market may not fully anticipate the challenges AKBA faces in achieving profitability.
Management is on track with expanding Vafseo revenue, but Auryxia revenues are declining due to competition. The trajectory towards profitability is uncertain, as recent results show a significant net loss.
The long-term thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS, which could influence AKBA's momentum. Additionally, any cuts in guidance from management could negatively impact sentiment and expectations.
Over the next 1 to 3 years, AKBA's performance will depend on its ability to navigate competitive pressures and achieve profitability. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide insights into revenue trends and management's strategy. It can shift investor sentiment.
Confirms one read:Earnings report shows revenue growth and positive guidance for future quarters.
Confirms the other:Earnings report shows revenue drop and bad outlook for future quarters.
Why it matters: Growth in Vafseo revenues is key for Akebia's financial health. A jump above $20 million would show strong market acceptance.
Confirms:Vafseo revenues exceed $20 million in Q2 2026.
Disproves:Vafseo revenues remain below $15 million in Q2 2026.
Why it matters: Profitability is a main goal for Akebia. It impacts investor trust and funding.
Confirms one read:Q2 earnings show a way to profitability with smaller losses.
Confirms the other:Q2 earnings report shows bigger losses with no clear way to profitability.
Why it matters: Making a profit is important for Akebia's future and for investor trust.
Confirms one read:Operating costs fall while revenue rises. This leads to positive EBITDA.
Confirms the other:Operating costs rise without revenue growth. This results in negative EBITDA.
Why it matters: Strong growth in Vafseo revenue is key to Akebia's overall growth strategy. It shows market acceptance and demand.
Confirms:Vafseo's revenue grows more than 10% each quarter from dialysis access.
Disproves:Vafseo revenue growth falls below 0% quarter over quarter.
Why it matters: Completing enrollment is important for quick data release. It shows progress in Akebia's kidney disease work.
Confirms:Enrollment of 60 patients in the praliciguat Phase 2 trial is completed by Q3 2026.
Disproves:Enrollment is not completed by Q3 2026.
Why it matters: A big drop in Auryxia revenues shows strong competition from generics. This could affect overall finances.
Confirms:Auryxia revenues decline more than 20% YoY in Q2 2026.
Disproves:Auryxia revenues decline less than 10% YoY in Q2 2026.
Why it matters: Topline data will show how well Vafseo works compared to ESAs. This is key for future growth.
Confirms one read:Topline data from VOCAL trial shows positive results for Vafseo.
Confirms the other:Topline data from VOCAL trial shows negative results for Vafseo.
